Straits Times Index
3,110.73 +36.47 (+1.19%) S&P 500
4,604.37 +18.78 (+0.41%) Dow
36,247.87 +130.47 (+0.36%) Nasdaq
14,403.97 +63.97 (+0.45%) Bitcoin USD
43,775.66 +69.38 (+0.16%) CMC Crypto 200
914.81 +18.10 (+2.02%)
Aeterna Zentaris Inc. (AEZS)
| Previous close | 2.3900 |
| Open | 2.2900 |
| Bid | 1.5500 x 900 |
| Ask | 2.6800 x 1000 |
| Day's range | 2.1702 - 2.4154 |
| 52-week range | 1.3600 - 3.9900 |
| Volume | |
| Avg. volume | 10,596 |
| Market cap | 10.683M |
| Beta (5Y monthly) | 2.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.8100 |
| Earnings date | 09 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.00 |
GlobeNewswireAeterna Zentaris Reports Third Quarter 2023 Financial Results
- Launch of Ghryvelin™ in a number of key countries in the European Economic Area - Approval of Macrilen® in South Korea in September - Ended the quarter with $38.8 million in cash, expected to fund operations and advancement of priority pipeline programs into 2025 TORONTO, ONTARIO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmac
ZacksAeterna Zentaris (AEZS) Reports Q2 Loss, Tops Revenue Estimates
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 40.23% and 104.18%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksAeterna (AEZS) Falls 5% on US Sales Halt of Growth Hormone Drug
Aeterna Zentaris (AEZS) announces halting sales of adult growth hormone deficiency diagnosis drug, Macrilen, in the United States in the absence of a commercialization partner. Stock down 5%.
